NCT06566807View on ClinicalTrials.gov

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 25, 2024

Primary Completion Date

August 10, 2026

Study Completion Date

August 10, 2028

Conditions
Marginal Zone Lymphoma
Interventions
DRUG

Orelabrutinib, obinutuzumab

orelabrutinib，150mg，D1-D28 obinutuzumab，1000mg，D1、D8、D15/cycle1 D1/cycle2-6 . The patients will be treated with 6 cycles of O2 regimen. Patients with CR/PR after 6 cycles of O2 treatment will be treated with 1 year of single-agent orelabrutinib regimen.

Trial Locations (1)

210000

RECRUITING

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University#Huai'an First People's Hospital#, Huai'an

All Listed Sponsors
lead

Huai'an First People's Hospital

OTHER